Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

258.05 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Microsoft, Snap And 2 Other Stocks Insiders Are Selling
The S&P 500 closed lower more than 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Biotech Is Back With Guggenheim Upgrade: What You Need To Know
Guggenheim Partners upgraded shares of Biogen Inc (NASDAQ: BIIB) to Buy, citing the company's potential for growth driven by its Alzheimer's disease (AD) and major depressive disorder (MDD)... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
Via Benzinga
Looking At Biogen's Recent Unusual Options Activity
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today
Via Benzinga
Biogen Earnings Perspective: Return On Capital Employed
Via Benzinga
These Analysts Revise Price Targets On Biogen Following Q1 Results
Biogen Inc. (NASDAQ: BIIB) reported results for its first quarter. 
Via Benzinga
Despite Its Falling 92%, Cathie Wood Is Buying More of This Growth Stock
Wood is betting that Ginkgo Bioworks' biofoundry can scale up enough to become profitable. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
Microsoft, Meta, Cloudflare and Crocs were among the many big movers. 
Via Investor's Business Daily
Biogen On The Hunt
Biogen is in the process of culling its pipeline to prepare for its upcoming deal making. What is happening and what does it mena? 
Via Talk Markets
Earnings Outlook For Biogen
Via Benzinga
What Does Biogen's Debt Look Like?
Via Benzinga
P/E Ratio Insights for Biogen
Via Benzinga
Is Biogen Stock a Buy Now?
The company's fascinating saga in the Alzheimer's disease drug market continues. 
Via The Motley Fool
The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy
Here are three biotech stocks with promising innovations that could provide catalysts for their respective stocks in 2023 
Via InvestorPlace
Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA
The FDA approved Biogen Inc's (NASDAQ: 
Via Benzinga
Alphabet To Rally Around 36%? Here Are 10 Other Analyst Forecasts For Wednesday
Morgan Stanley raised the price target for Alphabet Inc. (NASDAQ: GOOGL) from $135 to $140. Morgan Stanley analyst Brian Nowak maintained an Overweight rating. Alphabet shares fell 1% to $102.83 in... 
Via Benzinga
What's Going On With Biogen Stock Tuesday?
Biogen Inc (NASDAQ: BIIB) shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon.  
Via Benzinga
Biogen Inc. Beats Q1 Earnings And Revenue Estimates
Biogen Inc. came out with quarterly earnings of $3.40 per share. 
Via Talk Markets
Leqembi Sales To Propel Biogen Stock To New Heights, Says Bullish Analyst
Via Benzinga
Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs
Via Benzinga
Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful
The company is hopeful for maintenance dosing and a new injection of the drug. 
Via Investor's Business Daily
3 Top Biotech Stocks Defying the Bear Market
All three companies have therapies with strong sales potential. 
Via The Motley Fool
Why Shares of Keros Therapeutics Jumped This Week
The company appointed a new director and an analyst reiterated his position on the stock. 
Via The Motley Fool
Biogen To Report Q1 Earnings: Here's What To Expect
We expect Biogen to beat expectations when it reports first-quarter 2023 results on Apr. 25 before the market opens. In the last reported quarter, the company delivered an earnings surprise of 15.38%. 
Via Talk Markets
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid... 
Via Benzinga
Better Big Biotech Buy: Biogen vs. Vertex
One is slightly cheaper than the other. 
Via The Motley Fool
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 17, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.